DUBLIN, Sept. 17, 2021 /PRNewswire/ -- The "Global Research Antibodies Market Report 2021" report has been added to ResearchAndMarkets.com's offering.
The global research antibodies market size is expected to reach USD 5.9 billion by 2028 and is expected to expand at a CAGR of 6.4% from 2021 to 2028.
Major market drivers include a rise in R&D initiatives undertaken by biopharmaceutical and biotechnology companies and government bodies, an increase in neurobiology and stem cell research, availability of technologically advanced products, and strategic collaborations among various key players.
An increase in the usage of research antibodies to develop therapies for various chronic and infectious diseases, including COVID-19, is anticipated to boost the market growth during the forecast period. For instance, in June 2019, the Institute of Life Sciences (ILS, India) developed antibodies against chikungunya viral infection.
These antibody structures were developed to aid scientists in understanding various aspects of virus pathogenesis entailing further research on antiviral therapies. Growing government funds and initiatives for R&D are anticipated to fuel market growth during the forecast period in the Asia Pacific region. According to the 2018-2019 Australian Budget, approximately USD 94 million was estimated for four years for new industry collaborations, research as well as new biomedical and medical programs.
Additionally, a rise in funds invested by pharmaceutical and biotechnology companies to enhance proteomics and genomics research is expected to boost market growth.
Research Antibodies Market Report Highlights
In 2020, primary antibodies held a dominant share in terms of revenue in the product segment owing to greater specificity, therefore, leading to increase adoption in R&D activities
Monoclonal antibodies captured a substantial share in 2020, as they offer higher sensitivity for the detection of antigens and also showcase efficient staining properties for various applications
The neurobiology segment is expected to witness exponential growth over the forecast period owing to the increasing prevalence of diseases that have limited treatment options and the rise in R&D activities by biotech companies and academic institutes
Pharmaceutical and biotechnology companies were dominant in terms of revenue amongst all end-users in 2020, owing to the increased adoption of research antibodies in drug development and discovery
In 2020, North America accounted for the substantial revenue share which is attributable to the high presence of many biotechnologies as well as biopharmaceutical manufacturers, research academies, and laboratories
Market Driver Analysis
Increasing Investment In R&D
Growing Stem Cells And Neurobiology Research
Increase In Research Academies And Industry Collaborations
Rise In The Availability Of Technologically Advanced Products
Rise In Proteomics And Genomics Research
Market Restraint Analysis
Stringent Government Regulations
High Cost Of Research Antibodies
Market Opportunities Analysis
Increasing Opportunities In Various Emerging Markets
Growing Demand For Personalized Medicines
Rising Focus On Biomarker Discovery
Market Challenges Analysis
Quality Concerns Of Research Antibodies
Time And Cost Intensive Process Of Antibody Development
Pricing Pressures Faced By Major Market Players
Becton Dickinson & Company
Thermo Fisher Scientific, Inc
Cell Signalling Technology, Inc.
F.Hoffmann La Roche Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/scbht7
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-5-9-bn-research-antibodies-market-to-2028-rising-focus-on-biomarker-discovery--growing-demand-for-personalized-medicines-301379622.html
SOURCE Research and Markets